Loading...
Loading...
VCNX| Name | Value |
|---|---|
| Revenues | 50.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 50.0K |
| Operating Expense | 5,169.0K |
| Operating I/L | -5,119.0K |
| Other Income/Expense | 41.0K |
| Interest Income | 0.0K |
| Pretax | -5,078.0K |
| Income Tax Expense | -59.0K |
| Net Income/Loss | -5,019.0K |
Vaccinex, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab, is a humanized monoclonal antibody undergoing clinical trials for non-small cell lung cancer, head and neck squamous cell carcinoma, Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody for the treatment of multiple sclerosis and other autoimmune disorders.
